Estrogen levels do not rise for transgender men treated with testosterone therapy
BOSTON– Testosterone therapy is not associated with a rise in estrogen levels among transgender men, according to a new study led by Boston Medical Center (BMC). In fact, the researchers observed an initial decline in estrogen levels, which later stabilized and remained within the normal range during the study's six-year period. Published online in Endocrine Practice, the results support that there are no additional risks to female reproductive tissues during testosterone therapy in transgender men.
Current treatment guidelines for transgender men using testosterone therapy suggest that there is a potential need for estrogen lowering strategies, including the removal of the uterus or ovaries, to lower the reproductive health risks. Higher estrogen levels have been shown to be a risk factor for endometrial cancer, pelvic pain, and other health complications. This study suggests that estrogen reducing strategies may not be necessary, and testosterone therapy alone can be a safe and effective treatment for transgender men.
The study followed the health of 24 transgender men over six years who were treated with testosterone therapy at Boston Medical Center. Researchers checked participants' estrogen and testosterone levels every three months for the first year of the study, and every six months for the following years. Most of the patients were starting testosterone therapy at the beginning of the study, and researchers were able to compare their base-line estrogen levels to those seen throughout treatment.
The study is the first to demonstrate how estrogen levels respond to testosterone treatment in transgender men over an extended period of time. Future research should observe these trends among a larger sample of participants.
"There are no nationally representative data sets to prove the efficacy of hormone therapy," said Joshua Safer, MD, former medical director of the Center for Transgender Medicine and Surgery at BMC. "Clinic-based studies like this can inform best-practice recommendations and help transgender men feel confident in the safety of their care."
About Boston Medical Center
Boston Medical Center is a private, not-for-profit, 487-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. It is the largest and busiest provider of trauma and emergency services in New England. Boston Medical Center offers specialized care for complex health problems and is a leading research institution, receiving more than $116 million in sponsored research funding in fiscal year 2017. It is the 15th largest recipient of funding in the U.S. from the National Institutes of Health among independent hospitals. In 1997, BMC founded Boston Medical Center Health Plan, Inc., now one of the top ranked Medicaid MCOs in the country, as a non-profit managed care organization. Boston Medical Center and Boston University School of Medicine are partners in the Boston HealthNet – 14 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit http://www.bmc.org.